Losartan acute kidney injury
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Acute Kidney Injury: Protective Mechanisms and Therapeutic Potential
Introduction to Acute Kidney Injury (AKI) and Losartan
Acute kidney injury (AKI) is a significant clinical problem characterized by a rapid decline in kidney function. It can lead to severe complications, including chronic kidney disease (CKD) and increased mortality. Losartan, an angiotensin II type 1 receptor (AT1R) blocker, has been studied extensively for its potential protective effects against AKI.
Losartan's Role in Reducing Ischemia/Reperfusion Injury
Ischemia/reperfusion (I/R) injury is a common cause of AKI. Studies have shown that losartan can mitigate the damage caused by I/R injury. In a study involving male Wistar rats, losartan administration before and after I/R significantly reduced serum urea nitrogen (BUN), creatinine (Cr), and other markers of kidney damage. This suggests that losartan, possibly in combination with Ang 1-7, can protect the kidneys from I/R-induced damage .
Prevention of AKI to CKD Transition
One of the critical concerns with AKI is its potential to progress to CKD. Research using a murine model has demonstrated that losartan can reduce the progression of CKD following AKI. Mice treated with losartan showed reduced mortality, blood pressure, albuminuria, azotemia, and kidney fibrosis compared to those receiving a vehicle. This indicates that losartan can effectively prevent the transition from AKI to CKD by inhibiting AT1a receptor signaling Cheng2016Rodríguez-Romo2016.
Improvement in Renal Blood Flow and Oxygen Delivery
Losartan has also been shown to improve renal blood flow (RBF) and oxygen delivery (RDO2) following hypotensive events induced by anesthesia. In a study with pigs, losartan treatment resulted in better recovery of RBF and RDO2 compared to vehicle-treated animals. This suggests that losartan can counteract the angiotensin II-mediated renal vasoconstriction that occurs during hypotension, thereby protecting renal function .
Antioxidant Defense and Structural Protection
Losartan's protective effects extend to enhancing antioxidant defenses and improving renal structure. In hypertensive rats subjected to renal ischemia, losartan treatment increased creatinine and urea clearance, reduced lipid peroxidation, and improved the activity of antioxidant enzymes. Additionally, losartan reduced cortico-medullary necrosis and tubular dilatation, indicating its role in preserving kidney structure and function .
Molecular Mechanisms and Gene Expression
The molecular mechanisms underlying losartan's protective effects involve significant alterations in gene expression. In a study analyzing mRNA profiles in ischemic AKI rat kidneys, losartan treatment was found to modulate the expression of genes involved in inflammation, oxidative stress, and apoptosis. This includes the downregulation of pro-inflammatory and pro-apoptotic genes, which contributes to its renoprotective effects Wu2019Fang2019.
Conclusion
Losartan has demonstrated significant potential in protecting against acute kidney injury through various mechanisms, including reducing ischemia/reperfusion damage, preventing the transition to chronic kidney disease, improving renal blood flow and oxygen delivery, enhancing antioxidant defenses, and modulating gene expression. These findings highlight the therapeutic potential of losartan in managing AKI and preventing its long-term complications.
Sources and full results
Most relevant research papers on this topic